Dr. Petkovich is a co-founder of Cytochroma and has provided scientific guidance as a consultant until 2006 when he joined the Company as a full-time Chief Scientific Officer (CSO). Dr. Petkovich served as a Director of the Company until his appointment as CSO. Dr. Petkovich has been involved in all of the Company’s efforts to raise capital and played a pivotal role in completing Cytochroma’s first license agreement (with Allergan, Inc.) and served as Chair of the Joint Research Management Committee established under this agreement. Dr. Petkovich received his B.Sc. from McMaster University in 1981 and Ph.D. in Biochemistry in 1986 from the University of Toronto. He was a post-doctoral fellow in the laboratory of Dr. Pierre Chambon in Strasbourg, France from 1986 to 1989. He moved to Queen's University in 1990 to join the Departments of Biochemistry and Pathology and was appointed Full Professor in 1998. Dr. Petkovich is an expert in small molecule signaling, nuclear receptors and metabolism and much of his work since 1981 has focused on vitamins D and A. Dr. Petkovich discovered the fundamental mechanism of action of vitamin A by cloning the first receptor for the vitamin A metabolite, retinoic acid and further went on to characterize a family cytochrome P450 enzymes critical for modulating retinoic activity. These discoveries are cited as major breakthroughs in the vitamin A field.